InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,870.62
(
-1.32%
)
US TECH 100
19,880.00
(
-2.30%
)
Dow Jones
43,444.99
(
-0.70%
)
Brent Oil
71.25
(
0.00%
)
Bitcoin
90,259.68
(
-0.35%
)
Post# of 253644
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

jq1234

Send PM Follow Ignore
Followers 68
Posts 4505
Boards Moderated 0
Alias Born 12/13/2009

jq1234

Re: jq1234 post# 176702

Saturday, 04/12/2014 2:29:39 AM

Saturday, April 12, 2014 2:29:39 AM

Post# of 253644
ABBV/ENTA TURQUOISE-II cirrhotic patients 12-week: Overall SVR12=92% for 3-DAA plus RBV. For trt naive, SVR12=94%; for trt experienced, SVR12=90%.

http://www.nejm.org/doi/pdf/10.1056/NEJMoa1402869

[Generally speaking similar to ION-1, 2 cirrhotic patients taking consideration ION-2 included some Incivek/Victrelis treated.]

SAPPHIRE-I: trt naive.

http://www.nejm.org/doi/pdf/10.1056/NEJMoa1315722

SAPPHIRE-II: trt experienced.

http://www.nejm.org/doi/pdf/10.1056/NEJMoa1401561

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up